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Abstract: Because of unspecific diagnostic criteria, there is much controversy around narcolepsy type
2, its existence and its frequency. With this retrospective and purely descriptive study, we aimed to
compare the frequency of narcolepsy type 2 compared to the well-described narcolepsy type 1, in a large
(n = 3,782) retrospective sample from a single tertiary sleep centre. After 2 weeks washout of sleep-
wake active medication, all patients with excessive daytime sleepiness (n = 1,392) underwent 2 weeks
actigraphy, polysomnography and multiple sleep latency test, and all diagnoses were made along current
diagnostic criteria. Narcolepsy type 1 was diagnosed in 91 patients, and 191 patients without cataplexy
had multiple sleep latency test (MSLT) results indicating narcolepsy. After exclusion of shift work
syndrome (n = 19), suspected insufficient sleep syndrome (n = 128), delayed sleep phase syndrome (n =
4) and obstructive sleep apnea (n = 34), six patients were diagnosed with narcolepsy type 2, of whom two
patients later developed narcolepsy type 1. Altogether, our observations suggest that narcolepsy type 2
exists, but its frequency may be much lower compared to narcolepsy type 1. In addition, they emphasize
the importance of scrupulously excluding other potential causes of sleepiness, if possible, with 2-week
actigraphy and polysomnography.
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Because of unspecific diagnostic criteria, there is much controversy around narcolepsy 
type 2, its existence and its frequency. With this retrospective and purely descriptive 
study, we aimed to compare the frequency of narcolepsy type 2 compared to the well-
described narcolepsy type 1, in a large (n=3782) retrospective sample from a single 
tertiary sleep center. After 2 weeks wash-out of sleep-wake active medication, all 
patients with excessive daytime sleepiness (n=1392) underwent 2 weeks actigraphy, 
polysomnography, and multiple sleep latency test, and all diagnoses were made along 
current diagnostic criteria. Narcolepsy type 1 was diagnosed in 91 patients, and 191 
patients without cataplexy had MSLT results indicating narcolepsy. After exclusion of 
shift work syndrome (n=19), suspected insufficient sleep syndrome (n=128), delayed 
sleep phase syndrome (n=4), and obstructive sleep apnea (n=34), 6 patients were 
diagnosed with narcolepsy type 2, whereof 2 patients later developed narcolepsy type 
1. Altogether, our observations suggest that narcolepsy type 2 exists, but its frequency 
may be much lower compared to narcolepsy type 1. In addition, they emphasize the 
importance of scrupulously excluding other potential causes of sleepiness, if possible 
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Narcolepsy type 1 is a very well defined disorder, caused by an almost total loss of 
hypothalamic hypocretin (orexin) levels. It presents with sleepiness, cataplexy, 
fragmented nocturnal sleep, and other associated symptoms such as sleep paralysis 
and hypnagogic/hypnopompic hallucinations (AASM, 2014; Bassetti, 2019). This form 
of narcolepsy is diagnosed in sleepy patients with pathologically reduced cerebrospinal 
fluid hypocretin (orexin) levels or when typical multiple sleep latency tests (MSLT) 
findings are accompanied by pathognomonic cataplexy (AASM, 2014). The prevalence 
is around 2-5 per 10’000 individuals (Bassetti, 2019). 
On the other hand, narcolepsy type 2 is much more difficult to diagnose (Baumann, 
2014; Bassetti, 2019). It lacks pathognomonic symptoms such as cataplexy, and 
cerebrospinal fluid levels are normal, if measured. Thus, the current diagnostic criteria 
require chronic excessive daytime sleepiness, absent cataplexy, typical MSLT findings 
with a mean sleep latency below 8 minutes and at least 2 sleep onset REM periods, 
whereof a polysomnography sleep onset REM (defined as REM onset latency ≤15 min) 
can be counted as well. In addition, the criteria require that the symptoms shall not be 
“better explained by other causes such as insufficient sleep, obstructive sleep apnea, 
delayed sleep phase disorder, or the effect of medication or substances or their 
withdrawal” (AASM, 2014). 
Due to the lack of specific criteria and biomarkers, narcolepsy type 2 is still widely 
debated. It remains unclear whether narcolepsy type 2 is more, equally, or less 
frequent than narcolepsy type 1. In addition, there is an ongoing debate whether 
narcolepsy type 2 is merely a transient diagnosis until cataplexy - i.e. narcolepsy type 
1 – emerges (Goldbart, 2014; Baumann, 2014). The observation of a poor test-retest 
reliability of the MSLT particularly in narcolepsy type 2 adds to diagnostic uncertainty 




(Trotti, 2013; Ruoff, 2018). In particular, it has been shown that chronic sleep restriction 
and shift work often produce narcolepsy-like MSLT findings (Marti, 2009; Goldbart, 
2014). 
In a cross-sectional laboratory-based analysis in a sample of 539 people, the 
prevalence of multiple sleep onset REM periods was 3.9%, particularly in patients with 
a mean sleep latency below 5 minutes (Singh, 2006). Given their findings, the authors 
concluded that subpopulations with excessive sleepiness including shift workers, 
young adults with chronic sleep restriction, and patients with sleep apnea, are likely to 
have a greater prevalence of sleep onset REM. Based on narcolepsy-like MSLT 
findings in 5.9% of males and 1.1% of females, all without cataplexy, in another 
community-based cohort of 556 subjects, the authors concluded that narcolepsy type 
2 might be highly prevalent, or that MSLT might produce a large number of false-
positive results (Mignot, 2006). In this study, however, shift work syndrome and chronic 
sleep restriction were not systematically excluded. In the same cohort, a later study 
aimed to exclude patients with shift work syndrome and short sleep and still found a 3-
fold larger prevalence of narcolepsy type 2 compared to type 1 (Goldbart, 2014). 
Nevertheless, actigraphy measures were not available in this study. 
Thus, we aimed to compare the frequencies of both types of narcolepsy in a large 
retrospective single-center cohort, which has been examined with actigraphy, 
polysomnography, and MSLT. 
 
Methods 
Within this study that has been approved by the local ethical committee, we analyzed 
3782 patients who have been examined with polysomnography in the sleep laboratory 
of the neurology department in our hospital between fall 2002 and early 2020, and 




applied the current diagnostic criteria to all patients (AASM, 2014). Prior to sleep 
laboratory examinations, all patients with chronic excessive daytime sleepiness were 
washed out for 2 weeks of CNS active medications which might cause or contribute to 
excessive daytime sleepiness or to altered sleep laboratory findings. In addition, all 
patients underwent extensive history-taking and a neurological examination in the 
outpatient unit, and filled out a set of standardized questionnaires (including the 
Epworth sleepiness scale, Fatigue severity scale, Hospital Anxiety and Depression 
Scale). 
Patients were examined by the means of 2 weeks actigraphy, followed by video-
polysomnography and an MSLT, as described before (Imbach, 2015). In patients with 
narcolepsy-like MSLT who did not qualify for narcolepsy type 1, we required the 
exclusion of disorders that can produce such MSLT findings. In particular, we strived 
for excluding insufficient sleep syndrome and shift work syndrome which both may 
present with narcolepsy-like MSLT findings (Marti et al., 2009; Mignot, 2006), but also 
for excluding sleep apnea and circadian sleep-wake disorders (AASM, 2014; Bassetti, 
2019). In patients with excessive daytime sleepiness who had a pathological MSLT 
with low mean sleep latency (< 8 minutes) and multiple sleep onset REM periods, and 
who slept at least 2 hours more during weekends, we evaluated by history-taking 
whether sleepiness was relieved in times without work, e.g during holidays or during 
unemployement. In patients who fulfilled all these requirements and therefore in line 
with the current diagnostic criteria, we diagnosed suspected insufficient sleep 
syndrome (AASM 2014, Baumann-Vogel 2020). Excessive daytime sleepiness due to 
shift work syndrome was diagnosed based on history, actigraphy and MSLT findings, 
as suggested by the current diagnostic criteria (AASM, 2014). In sleepy patients with 
increased sleep need (at least 11 hours per 24 hours) and/or sleep inertia, we 
suspected idiopathic hypersomnia (AASM, 2014; Baumann, 2014). For the diagnosis 




of obstructive sleep apnea, and again in accordance with the current diagnostic criteria, 
we required an apnea-hypopnea index of at least 5 on polysomnography in patients 
with EDS and a history of nocturnal awakenings with breath holding, gasping, choking 




Among 1392 patients with excessive daytime sleepiness (as defined by an Epworth 
sleepiness scale value of at least 11 points) and without significant neurological or 
psychiatric comorbidities, we identified 91 patients with narcolepsy type 1 (2.4% of the 
examined population), all of them with typical MSLT findings (Figure 1). In addition, we 
found the combination of a mean sleep latency <8 minutes plus multiple sleep onset 
REM periods in another 191 patients (5.1%). Of these, history-taking and actigraphy 
recordings suggested insufficient sleep syndrome in 128 patients, shift work syndrome 
in 19 patients, delayed sleep phase syndrome in 4 patients, and 34 patients were 
diagnosed with obstructive sleep apnea. Two longitudinally followed patients evolved 
into narcolepsy type 1. In 4 patients without findings hinting at such other disorders, 
we diagnosed narcolepsy type 2. These four patients are summarized in Table 1, all of 
them were HLA-DQB1*0602-positive, all of them male. One elderly patient (no 3) 
developed narcolepsy symptoms after a tick bite.  
 
Discussion 
The findings of this study suggest that narcolepsy type 2 exists, but its frequency may 
be up to 20-25x lower compared to narcolepsy type 1. For the sleep clinician, this 




observation shall motivate to scrupulously exclude other potential reasons for 
narcolepsy-like MSLT findings, particularly shift work and insufficient sleep syndrome, 
but also circadian disorders and sleep apnea. This is important, as these disorders 
require markedly different therapies, spanning from non-pharmacological sleep 
hygiene to stimulants or continuous positive airway pressure treatment. For the sleep 
scientist, the findings of the present study may provoke a critical reading of reports on 
narcolepsy type 2, if actigraphy and other tests and parameters have not been used to 
exclude other causes of sleepiness and enhanced REM sleep pressure. 
To achieve a solid diagnosis, objective assessments of rest-activity rhythms with 2-
week actigraphy are most likely superior to history taking or sleep logs. Given 
observations from human studies, the habitual sleep need of young people might be 
around 9 hours per day, and 7.5 hours in the elderly (Klerman, 2008). Many of us sleep 
much less, which makes insufficient sleep syndrome most probably a very prevalent 
phenomenon (Baumann-Vogel et al., 2020). In addition, a sleep stage sequence 
WAKENREM1REM on MSLT and even more a short REM sleep latency during 
polysomnography are strong indicators for the presence of narcolepsy and should be 
considered as well (Andlauer et al., 2013; Marti, 2009).  
In a recent opinion statement, some European colleagues addressed the diagnostic 
challenges around narcolepsy type 2 and proposed to replace “narcolepsy type 1” and 
“narcolepsy type 2” by “narcolepsy” (Lammers et al., 2020). They suggest to diagnose 
definite narcolepsy in the presence of excessive daytime sleepiness in combination 
with hypocretin deficiency and/or typical cataplexy with typical MSLT results. This 
corresponds to the current diagnostic criteria of narcolepsy type 1 (AASM, 2020). To 
diagnose probable narcolepsy, their proposed criteria require excessive daytime 
sleepiness and either (1) typical cataplexy and a sleep latency on MSLT below 8 




minutes or multiple sleep onset REM periods, or (2) hypnagogic hallucinations and/or 
sleep paralysis and/or disturbed nocturnal sleep and an MSLT with an even shorter 
mean sleep latency (<5 minutes) or with even more (>2) sleep onset REM periods, 
plus positive HLA DQB1*0602 testing and exclusion of other causes of sleepiness 
(Lammers, 2020). Although their proposal did not include neither the sequence of sleep 
stages during MSLT nor sleep onset REM during polysomnography which might have 
further sharpened the diagnostic criteria, and although such an approach mixes a 
group of very well-defined patients with a potentially mixed bag of hypersomnia 
patients, this proposal would at least most likely contribute to lower numbers of false 
positive narcolepsy diagnoses (Marti et al., 2009; Andlauer, 2014). Whatever the next 
generation of diagnostic criteria for narcolepsy might look like, given the present and 
previous findings, such new criteria for narcolepsy without cataplexy or without 
hypocretin deficiency must put a stronger emphasis on the exclusion of other disorders, 
and therefore should specifically recommend related examinations (polysomnography, 
actigraphy).  
This retrospective analysis has limitations. First of all, it does not solve the question 
what narcolepsy type 2 is. Is it a separate disease, a subtype of narcolepsy, a 
prodromal stage of narcolepsy type 1, or a form of idiopathic hypersomnia with normal 
night sleep periods and without sleep inertia? Second, we suspected insufficient sleep 
syndrome along the current diagnostic criteria, but in the majority of patients, we did 
not prove this diagnosis by extending sleep times which is expensive and burdensome 
(Baumann-Vogel et al., 2020). On the other hand, we have information from all patients 
with suspected insufficient sleep syndrome that sleepiness remits or significantly 
improves during holidays, which is in strong favor of this diagnosis rather than 
narcolepsy. Third, another limitation concerns the assessments in a preselected 
referred clinical population. We therefore cannot estimate a population-based 




prevalence, but only deduce that narcolepsy type 2 may be much rarer than type 1. 
Last not least, a fourth limitation is the fact that we do not perform HLA assessments 
in all sleepy patients, mostly because of the high costs which are not regularly covered 
by insurance companies. Nevertheless, given the low specificity of positive HLA 
DQB1*0602 results for narcolepsy, we consider this limitation as minor (Hong, 2006). 
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Figure  1.  Flowchart illustrating the stepwise process of elimination finally leading to 
diagnosing 4 patients suffering from excessive daytime sleepiness (EDS) with narcolepsy 
type 2 (NC2). MSLT: multiple sleep latency test. NC1: narcolepsy type 1. 





Table 1. Characteristics of 4 patients with narcolepsy type 2. D.O.: Disease onset (age, years). Regular: regular rest-activity rhythm, without 
signs of shift work syndrome or circadian disorders. SOREM: sleep onset REM periods. MSLT: multiple sleep latency test. MSL: mean sleep 
latency. W>N1>R naps: no of MSLT naps with the sleep stage sequence WAKENREM1REM. TIB: time in bed. WD-WE: difference in TBI 
between weekdays and weekends. 
 
 Demographics Actigraphy  PSG MSLT       Serum 
No Sex Age D.O. Regular  Mean TIB WD-WE SOREM  MSL  SOREM W>N1>R naps HLA-DQBI*0601 
1 m 36 18 yes    8.4 hours 1.2 hours 0 3.5 min 2  1   positive 
2 m 32 13 yes    7.9 hours 0.9 hours 0 4.0 min 3  0   positive 
3 m 74 71 yes     8.6 hours 0.3 hours 1 4.3 min 4  2   positive 
4 m 16 14 yes    9.2 hours 2.6 hours 0 4.1 min 3   2   positive 
 
 
 
 
